Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Fey, M F ^a   Dreyling, M ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; CYTARABINE; CYTOSTATIC AGENT; DNA METHYLTRANSFERASE INHIBITOR; HEMOPOIETIC GROWTH FACTOR; HYDROXYUREA; IMMUNOMODULATING AGENT; LENALIDOMIDE; RETINOIC ACID; THYMOCYTE ANTIBODY;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AIRWAY OBSTRUCTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD ANALYSIS; BLOOD CELL COUNT; BONE MARROW EXAMINATION; CANCER CLASSIFICATION; CANCER INCIDENCE; CHROMOSOME ABERRATION; CHROMOSOME DISORDER; CLINICAL TRIAL; COMORBIDITY; CYTOGENETICS; DIABETES MELLITUS; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; ISCHEMIC HEART DISEASE; KARYOTYPE; LEUKAPHERESIS; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LOW DRUG DOSE; MOLECULAR GENETICS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADULT; ANTINEOPLASTIC AGENTS; EUROPE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; INCIDENCE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 77954317788     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq179     Document Type: Article

References (17)

1. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias: French-American-British Cooperative Group. Br J Haematol 1976; 33: 451-458.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization (WHO) classification of tumours: pathology and genetics of haematopoietic and lymphatic tissues. 3rd edition. Lyon, France: IARC Press 2001.
3. Swerdlow SH, Campo E, Harris NL et al. (eds): World Health Organization (WHO) classification of tumours: pathology and genetics of haematopoietic and lymphatic tissues. 4th edition. Lyon, France: IARC Press 2008.
4. Vardiman J, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
5. Pulsoni A, Iacobelli S, Bernardi S et al. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. Haematologica 2008; 93: 1025-1032.
6. Thomas X, Suciu S, Rio B et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 2007; 92: 389-396.
7. Kantarjian HM, O'Brien S, Huang X et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007; 109: 1133-1137.
8. Kantarjian HM, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
9. Amadori S, Suciu S, Jehn U et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27-34.
10. Cornelissen JJ, van Putten WL, Verdonck LF et al. Results of a HOVON/SAKK donor versus no donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle aged adults: benefits for whom? Blood 2007; 109: 3658-3666.
11. Lö wenberg B, van Putten W, Theobald M et al. (Dutch-Belgian Hemato-Oncology Cooperative Group, Swiss Group for Clinical Cancer Research). Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukaemia. N Engl J Med 2003; 349: 743-752.
12. Fenaux P, Chastang C, Chevret S et al. for the European APL Group: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-1200.
13. Bradstock KE, Matthews JP, Lowenthat RM et al. A randomized trial of highversus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481-488.
14. Basara N, Schulze A, Wedding U et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23: 635-640.
15. de Witte T, Suciu S, Brand R et al. Autologous stem cell transplantation in myelodysplastic syndromes. Semin Hematol 2007; 44: 274-277.
16. Breems DA, Lowenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol 2007; 44: 259-266.
17. Mrozek K, Marcucci G, Paschka P et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109: 431-448.